CRRL269-Reference-Cited by-同舟云学术

CRRL269

Published:2019-05-10 Issue:10 Volume:124 Page:1462-1472
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Chen Yang¹²,Harty Gail J.¹,Zheng Ye¹,Iyer Seethalakshmi R.¹,Sugihara Shinobu¹,Sangaralingham S. Jeson¹³,Ichiki Tomoko¹,Grande Joseph P.⁴,Lee Hon-Chi⁵,Wang Xiaoli⁵,Burnett John C.¹³

Affiliation:

1. From the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.

2. Mayo Clinic Graduate School of Biomedical Sciences (Y.C.), Mayo Clinic, Rochester, MN.

3. Department of Physiology and Biomedical Engineering (S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.

4. Department of Laboratory Medicine and Pathology (J.P.G.), Mayo Clinic, Rochester, MN.

5. Department of Cardiovascular Medicine (H.-C.L., X.L.W.), Mayo Clinic, Rochester, MN.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference52 articles.

1. Kidney disease: improving global outcomes (kdigo) acute kidney injury work group. Kdigo clinical practice guideline for acute kidney injury.;Kellum JA;Kidney I ntl Suppl,2012

2. Acute Kidney Injury and Risk of Heart Failure and Atherosclerotic Events

3. Epidemiology and Outcomes in Community-Acquired Versus Hospital-Acquired AKI

4. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study

5. Acute Kidney Injury Is Associated With Increased Long-Term Mortality After Cardiothoracic Surgery

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation;International Journal of Molecular Sciences;2023-05-10

2. EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM;2023-01-27

3. Natriuretic peptide pathways in heart failure: further therapeutic possibilities;Cardiovascular Research;2022-08-25

4. Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States;Biology;2022-06-03

5. Role of uromodulin and complement activation in the progression of kidney disease;Oncology Letters;2021-10-13